Notably, BRAF inhibitor vemurafenib or dabrafenib has achieved an objective response rate (ORR) of 33%–42% and mPFS of 5.5 to 7.3 months in BRAF V600E mutant NSCLC patients, respectively (17, 18). Here, BRAF is linked to non-small cell lung carcinoma.